Figure 1. Tissue Similarity Between Lung Tumors and Organs Affected by Autoimmune Toxic Effects.

Positive associations between tumor-tissue similarity score and organ-specific immune-related adverse effects in patients with non–small cell lung carcinoma treated with nivolumab (A) or pembrolizumab (B). Pearson correlation coefficient was R = 0.71 for nivolumab and R = 0.81 for pembrolizumab, and the P value was P = .003 for nivolumab and P = .001 for pembrolizumab.